Article

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

2020-05-03

Abstract excerpt

<h4>ABSTRACT</h4> Approximately 50% of human cutaneous melanomas carry activating mutations in the serine/threonine protein kinase BRAF. BRAF inhibitors (BRAFi) selectively target the oncogenic BRAF V600E/K and are effective in approximately 80% of patients carrying the mutation. However, resistance to BRAFi is common and emerges within a median time of 6-7 months of treatment and is prolonged to 11 months when...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 11e7b26d-34e1-5eb1-85ad-804f63eac940
DOI: 10.1101/2020.05.03.073627

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanomaDOI 10.1101/2020.05.03.073627Read

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaSemantic proximity Read

Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation eventsSemantic proximity Read

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTENSemantic proximity Read

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint InhibitorsSemantic proximity Read

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Semantic proximity Read

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1RSemantic proximity Read

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.Semantic proximity Read

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.Semantic proximity Read

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelSemantic proximity Read

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.Semantic proximity Read

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.Semantic proximity Read

POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulationSemantic proximity Read